Advertisement

International Urology and Nephrology

, Volume 50, Issue 12, pp 2261–2278 | Cite as

The benefits of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers combined with calcium channel blockers on metabolic, renal, and cardiovascular outcomes in hypertensive patients: a meta-analysis

  • Punnaka Pongpanich
  • Pasvich Pitakpaiboonkul
  • Kullaya Takkavatakarn
  • Kearkiat Praditpornsilpa
  • Somchai Eiam-Ong
  • Paweena SusantitaphongEmail author
Nephrology - Original Paper
  • 120 Downloads

Abstract

Background

The prevalence of hypertension and its associated complications are markedly growing. Most patients need more than one drug to achieve blood pressure (BP) target. However, most guidelines only focus on the first-line treatment. We conducted a meta-analysis to explore the benefits of angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin II receptor blockers (ARBs) combined with calcium channel blockers (CCBs) on metabolic, renal, and cardiovascular outcomes in hypertensive patients.

Methods

A systematic literature search was conducted in MEDLINE, Scopus, Cochrane Central Register of Controlled Trials, and Clinical Trials.gov (until April 7, 2016) to identify randomized controlled trials (RCTs) comparing the benefits of ACEIs/ARBs combined with CCBs versus other dual or triple combinations on clinical outcomes in hypertensive patients. Random effects models were used to compute the weighted mean difference (WMD) for continuous variables.

Results

Sixty RCTs (48,913 patients) were identified. When compared with other combinations, the combination of ACEIs/ARBs and CCBs had comparable WMD of systolic as well as diastolic BP (73 study arms) but provided better benefits on metabolic parameters, such as HDL, FBS, HbA1C, and serum uric acid; renal functions, including serum creatinine and estimated glomerular filtration rate; and cardiovascular diseases, including reduction of all cardiovascular events, myocardial infarction, and syncope/hypotension. A significant increase of serum potassium was observed.

Conclusion

The combination of ACEIs/ARBs with CCBs has superior benefits on metabolic, renal, and cardiovascular outcomes in hypertensive patients. Therefore, this combination should be considered whenever monotherapy does not achieve the guideline target.

Keywords

ACEIs ARBs CCBs Hypertension Clinical outcomes Meta-analysis 

Notes

Funding

This work was funded by Thailand research fund Career Development Grant #RSA5880067. Thailand.

Compliance with ethical standards

Conflict of interest

All authors have no conflict of interest relevant to the work.

Ethical approval

No approval of an ethics committee was required as this was a meta-analysis.

Informed consent

This article does not contain any studies with human participants performed by any of the authors and use the data from previous reports. Therefore, informed consent was not required.

Research involving human and animal participants

This article does not contain any studies with human participants performed by any of the authors.

Supplementary material

11255_2018_1991_MOESM1_ESM.tif (100 kb)
Supplementary Figure 1a Forest plot displaying the effect of the combination of ACEIs/ARBs and CCBs on change in serum creatinine (A), serum potassium (B), serum HDL (C), and HBA1C (D). (TIF 100 KB)
11255_2018_1991_MOESM2_ESM.tif (95 kb)
Supplementary Figure 1b (TIF 95 KB)
11255_2018_1991_MOESM3_ESM.tif (101 kb)
Supplementary Figure 1c (TIF 100 KB)
11255_2018_1991_MOESM4_ESM.tif (104 kb)
Supplementary Figure 1d (TIF 104 KB)
11255_2018_1991_MOESM5_ESM.pdf (632 kb)
Supplementary Table 1 (PDF 633 KB)

References

  1. 1.
    Morgan TO, Anderson AI, MacInnis RJ (2001) ACE inhibitors, beta-blockers, calcium blockers, and diuretics for the control of systolic hypertension. Am J Hypertens 14:241–247PubMedGoogle Scholar
  2. 2.
    Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brien E, Ostergren J, ASCOT investigators (2005) Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required vs. atenolol adding bendroflumethiazide as required in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOTBPLA) a multicentre randomised controlled trial. Lancet 366:895–906PubMedGoogle Scholar
  3. 3.
    Verdecchia P, Staessen JA, Angeli F, de Simone G, Achilli A, Ganau A, Mureddu G, Pede S, Maggioni AP, Lucci D, Reboldi G, Cardio-Sis investigators (2009) Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet 374(9689):525–533PubMedGoogle Scholar
  4. 4.
    Volpe M, Tocci G (2012) Rationale for triple fixed-dose combination therapy with an angiotensin II receptor blocker, a calcium channel blocker, and a thiazide diuretic. Vasc Health Risk Manage 8:371–380Google Scholar
  5. 5.
    Abraham HMA, White CM, White WB (2015) The Comparative efficacy and safety of the angiotensin receptor blockers in the management of hypertension and other cardiovascular diseases. Drug saf 38(1):33–54PubMedPubMedCentralGoogle Scholar
  6. 6.
    National Institute for Health and Care Excellence (2001) The clinical management of primary hypertension in adults: NICE clinical guideline. http://www.ehy.ee/docs/pics/NICE%20hypertension%202011.pdf. Accessed 4 Nov 2017
  7. 7.
    Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F, Task force members (2013) 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 31(7):1281–1357PubMedGoogle Scholar
  8. 8.
    Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson JG, Flack JM, Carter BL, Materson BJ, Ram CV, Cohen DL, Cadet JC, Jean-Charles RR, Taler S, Kountz D, Townsend RR, Chalmers J, Ramirez AJ, Bakris GL, Wang J, Schutte AE, Bisognano JD, Touyz RM, Sica D, Harrap SB (2014) Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich) 16:14–26Google Scholar
  9. 9.
    James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC Jr, Svetkey LP, Taler SJ, Townsend RR, Wright JT Jr, Narva AS, Ortiz E (2014) 2014 evidence-based guideline for the management of high blood pressure in adults—report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 311:507–520PubMedGoogle Scholar
  10. 10.
    Wu L, Deng SB, She Q (2014) Calcium channel blocker compared with angiotensin receptor blocker for patients with hypertension: a meta-analysis of randomized controlled trials. J Clin Hypertens (Greenwich) 16:838–845Google Scholar
  11. 11.
    Cicero AFG, Gerocarni B, Rosticci M, Borghi C (2012) Blood pressure and metabolic effect of a combination of lercanidipine with different antihypertensive drugs in clinical practice. Clin Exp Hypertens 34(2):113–117PubMedGoogle Scholar
  12. 12.
    Huang RS, Cheng YM, Zeng XX, Kim S, Fu P (2016) Renoprotective effect of the combination of renin-angiotensin system inhibitor and calcium channel blocker in patients with hypertension and chronic kidney disease. Chin Med J (England) 129:562–569Google Scholar
  13. 13.
    Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ, ACCOMPLISH Trial Investigators (2008) Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 359:2417–2428PubMedGoogle Scholar
  14. 14.
    Chi C, Tai C, Bai B, Yu S, Karamanou M, Wang J, Protogerou A, Blacher J, Safar ME, Zhang Y, Xu Y (2016) Angiotensin system blockade combined with calcium channel blockers is superior to other combinations in cardiovascular protection with similar blood pressure reduction: a meta-analysis in 20,451 hypertensive patients. J Clin Hypertens (Greenwich) 18:801–808Google Scholar
  15. 15.
    Cheng Y, Huang R, Kim S, Zhao Y, Li Y, Fu P (2016) Renoprotective effects of renin-angiotensin system inhibitor combined with calcium channel blocker or diuretic in hypertensive patients: a PRISMA-compliant meta-analysis. Medicine (Baltimore) 95(28):e4167.  https://doi.org/10.1097/MD.0000000000004167 CrossRefGoogle Scholar
  16. 16.
    Jennings DL, Kalus JS, Coleman CI, Manierski C, Yee J (2007) Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis. Diabet Med 24(5):486–493PubMedGoogle Scholar
  17. 17.
    Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsärinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S, ONTARGET investigators (2008) Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 372(9638):547–553PubMedGoogle Scholar
  18. 18.
    Kuenzli A, Bucher HC, Anand I, Arutiunov G, Kum LC, McKelvie R, Afzal R, White M, Nordmann AJ (2010) Meta-analysis of combined therapy with angiotensin receptor antagonists versus ACE inhibitors alone in patients with heart failure. PLoS ONE 5(4):e9946.  https://doi.org/10.1371/journal.pone.0009946 CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Ritter JM (2011) Dual blockade of the renin-angiotensin system with angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs). Br J Clin Pharmacol 71(3):313–315PubMedPubMedCentralGoogle Scholar
  20. 20.
    European Medicines Agency (2014) PRAC recommends against combined use of medicines affecting the renin-angiotensin (RAS) system. Pharmacovigilance Risk Assessment Committee. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2014/04/news_detail_002066.jsp&mid=WC0b01ac058004d5c1. Accessed 11 Apr 2014
  21. 21.
    Armstrong C (2014) JNC8 guidelines for the management of hypertension in adults. Am Fam Physician 90(7):503–504PubMedGoogle Scholar
  22. 22.
    Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary. Control Clin Trials 17:1–12PubMedGoogle Scholar
  23. 23.
    Huedo-Medina TB, Sanchez-Meca J, Marin-Martinez F, Botella J (2006) Assessing heterogeneity in meta-analysis: Q statistic or I2 index. Psychol Methods 11:193–206PubMedGoogle Scholar
  24. 24.
    Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634PubMedPubMedCentralGoogle Scholar
  25. 25.
    Antonios TF, Cappuccio FP, Markandu ND, Sagnella GA, MacGregor GA (1996) A diuretic is more effective than a beta- blocker in hypertensive patients not controlled on amlodipine and Lisinopril. Hypertension 27:1325–1328PubMedGoogle Scholar
  26. 26.
    Schneider M, Lerch M, Papiri M, Buechel P, Boehlen L, Shaw S, Risen W, Weidmann P (1996) Metabolic neutrality of combined verapamil-trandolapril treatment in contrast to beta-blocker-low-dose chlortalidone treatment in hypertensive type 2 diabetes. J Hypertens 14:669–677PubMedGoogle Scholar
  27. 27.
    de Leeuw PW, Notter T, Zilles P (1997) Comparison of different fixed antihypertensive combination drugs: a double-blind, placebo-controlled parallel group study. J Hypertens 15:87–91PubMedGoogle Scholar
  28. 28.
    Cifková R, Nakov R, Novozámská E, Hejl Z, Petrzílková Z, Poledne R, Stávek P, Compagnone D (2000) Evaluation of the effects of fixed combinations of sustained-release verapamil/trandolapril versus captopril/hydrochlorothiazide on metabolic and electrolyte parameters in patients with essential hypertension. J Hum Hypertens 14:347–354PubMedGoogle Scholar
  29. 29.
    Fernández R, Puig JG, Rodríguez-Pérez JC, Garrido J, Redon J, TRAVEND Study Group (2001) Effect of two antihypertensive combinations on metabolic control in type-2 diabetic hypertensive patients with albuminuria: a randomised, double-blind study. J Hum Hypertens 15:849–856PubMedGoogle Scholar
  30. 30.
    Suzuki H, Moriwaki K, Kanno Y, Nakamoto H, Okada H, Chen XM (2001) Comparison of the effects of an ACE inhibitor and alpha beta blocker on the progression of renal failure with left ventricular hypertrophy: preliminary report. Hypertens Res 24:153–158PubMedGoogle Scholar
  31. 31.
    Weir MR, Rosenberger C, Fink JC (2001) Pilot study to evaluate a water displacement technique to compare effects of diuretics and ACE inhibitors to alleviate lower extremity edema due to dihydropyridine calcium antagonists. Am J Hypertens 14:963–968PubMedGoogle Scholar
  32. 32.
    Malacco E, Piazza S, Carretta R, Di Somma S, Mugellini A, Bertocchi F, Palatini P, Italian Blood Pressure Study Group (2002) Comparison of benazepril-amlodipine and captopril-thiazide combinations in the management of mild-to-moderate hypertension. Int J Clin Pharmacol Ther 40(6):263–269PubMedGoogle Scholar
  33. 33.
    Quiñones-Galvan A, Pucciarelli A, Ciociaro D, Masoni A, Franzoni F, Natali A, Ferrannini E (2002) Metabolic effects of combined antihypertensive treatment in patients with essential hypertension. J Cardiovasc Pharmacol 40:916–921PubMedGoogle Scholar
  34. 34.
    Holzgreve H, Nakov R, Beck K, Janka HU (2003) Antihypertensive therapy with verapamil SR plus trandolapril versus atenolol plus chlorthalidone on glycemic control. Am J Hypertens 16:381–386PubMedGoogle Scholar
  35. 35.
    Mugellini A, Preti P, Zoppi A, Corradi L, Fogari E, Derosa G, Fogari R (2004) Effect of delapril-manidipine combination vs irbesartan-hydrochlorothiazide combination on fibrinolytic function in hypertensive patients with type II diabetes mellitus. J Hum Hypertens 18(10):687–691PubMedGoogle Scholar
  36. 36.
    de la Sierra A, Gil-Extremera B, Calvo C, Campo C, García-Puig J, Márquez E, Oliván J, Roca Cusachs A, Sanz de Castro S, Pontes C, Delgadillo J (2004) Comparison of the antihypertensive effects of the fixed dose combination enalapril 10 mg/nitrendipine 20 mg vs losartan 50 mg/hydrochlorothiazide 12.5 mg, assessed by 24-h ambulatory blood pressure monitoring, in essential hypertensive patients. J Hum Hypertens 18:215–222PubMedGoogle Scholar
  37. 37.
    Stergiou GS, Makris T, Papavasiliou M, Efstathiou S, Manolis A (2005) Comparison of antihypertensive effects of an angiotensin-converting enzyme inhibitor, a calcium antagonist and a diuretic in patients with hypertension not controlled by angiotensin receptor blocker monotherapy. J Hypertens 23:883–889PubMedGoogle Scholar
  38. 38.
    Agrawal R, Marx A, Haller H (2006) Efficacy and safety of lercanidipine versus hydrochlorothiazide as add-on to enalapril in diabetic populations with uncontrolled hypertension. J Hypertens 24:185–192PubMedGoogle Scholar
  39. 39.
    Bakris G, Molitch M, Hewkin A, Kipnes M, Sarafidis P, Fakouhi K, Bacher P, Sowers J, STAR Investigators (2006) Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care 29:2592–2597PubMedGoogle Scholar
  40. 40.
    Karotsis AK, Symeonidis A, Mastorantonakis SE, Stergiou GS, Home-Di-Plus Study Group (2006) Additional antihypertensive effect of drugs in hypertensive subjects uncontrolled on diltiazem monotherapy: a randomized controlled trial using office and home blood pressure monitoring. Clin Exp Hypertens 28:655–662PubMedGoogle Scholar
  41. 41.
    Fogari R, Corradi L, Zoppi A, Lazzari P, Mugellini A, Preti P, Rinaldi A (2007) Addition of manidipine improves the antiproteinuric effect of candesartan in hypertensive patients with type II diabetes and microalbuminuria. Am J Hypertens 20:1092–1096PubMedGoogle Scholar
  42. 42.
    Kereiakes DJ, Neutel JM, Punzi HA, Xu J, Lipka LJ, Dubiel R (2007) Efficacy and safety of olmesartan medoxomil and hydrochlorothiazide compared with benazepril and amlodipine besylate. Am J Cardiovasc Drugs 7:361–372PubMedGoogle Scholar
  43. 43.
    Poldermans D, Glazes R, Kargiannis S, Wernsing M, Kaczor J, Chiang YT, Yen J, Gamboa R, Fomina I (2007) Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension. Clin Ther 29:279–289PubMedGoogle Scholar
  44. 44.
    Shimosawa T, Gohchi K, Yatomi Y, Fujita T (2007) Effectiveness of add-on low-dose diuretics in combination therapy for hypertension: losartan/hydrochlorothiazide vs. candesartan/amlodipine. Hypertens Res 30:831–837PubMedGoogle Scholar
  45. 45.
    Bakris GL, Toto RD, McCullough PA, Rocha R, Purkayastha D, Davis P, GUARD (Gauging Albuminuria Reduction With Lotrel in Diabetic Patients With Hypertension) Study Investigators (2008) Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. Kidney Int 73:1303–1309PubMedGoogle Scholar
  46. 46.
    Fogari R, Derosa G, Zoppi A, Lazzari P, Corradi L, Preti P, Mugellini A (2008) Effect of delapril/manidipine vs olmesartan/hydrochlorothiazide combination on insulin sensitivity and fibrinogen in obese hypertensive patients. Intern Med 47:361–366PubMedGoogle Scholar
  47. 47.
    Fogari R, Derosa G, Zoppi A, Rinaldi A, Preti P, Lazzari P, Mugellini A (2008) Effects of manidipine/delapril versus olmesartan/hydrochlorothiazide combination therapy in elderly hypertensive patients with type 2 diabetes mellitus. Hypertens Res 31:43–50PubMedGoogle Scholar
  48. 48.
    Fogari R, Zoppi A, Mugellini A, Corradi L, Lazzari P, Preti P, Derosa G (2008) Comparative evaluation of effect of valsartan/amlodipine and atenolol/amlodipine combinations on atrial fibrillation recurrence in hypertensive patients with type 2 diabetes mellitus. J Cardiovasc Pharmacol 51:217–222PubMedGoogle Scholar
  49. 49.
    Roca-Cusachs A, Schmieder RE, Triposkiadis F, Wenzel RR, Laurent S, Kohlmann O Jr, Fogari R, MORE Study Group (2008) Efficacy of manidipine/delapril versus losartan/hydrochlorothiazide fixed combinations in patients with hypertension and diabetes. J Hypertens 26(4):813–818PubMedGoogle Scholar
  50. 50.
    Calhoun DA, Crikelair NA, Yen J, Glazer RD (2009) Amlodipine/valsartan/hydrochlorothiazide triple combination therapy in moderate/severe hypertension: secondary analyses evaluating efficacy and safety. Adv Ther 26:1012–1023PubMedGoogle Scholar
  51. 51.
    Fogari R, Zoppi A, Mugellini A, Corradi L, Lazzari P, Preti P, Derosa G (2009) Efficacy and safety of two treatment combinations of hypertension in very elderly patients. Arch Gerontol Geriatr 48:401–405PubMedGoogle Scholar
  52. 52.
    Ishimitsu T, Numabe A, Masuda T, Akabane T, Okamura A, Minami J, Matsuoka H (2009) Angiotensin-II receptor antagonist combined with calcium channel blocker or diuretic for essential hypertension. Hypertens Res 32:962–968PubMedGoogle Scholar
  53. 53.
    Kaneshiro Y, Ichihara A, Sakoda M, Kurauchi-Mito A, Kinouchi K, Itoh H (2009) Add-on benefits of amlodipine and thiazide in nondiabetic chronic kidney disease stage 1/2 patients treated with valsartan. Kidney Blood Press Res 32:51–58PubMedGoogle Scholar
  54. 54.
    Kohlmann O Jr, Roca-Cusachs A, Laurent S, Schmieder RE, Wenzel RR, Fogari R (2009) Fixed-dose manidipine/delapril versus losartan/hydrochlorothiazide in hypertensive patients with type 2 diabetes and microalbuminuria. Adv Ther 26(3):313–324PubMedGoogle Scholar
  55. 55.
    Matsui Y, Eguchi K, O’Rourke MF, Ishikawa J, Miyashita H, Shimada K, Kario K (2009) Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients. Hypertension 54:716–723PubMedGoogle Scholar
  56. 56.
    Reichek N, Devereux RB, Rocha RA, Hilkert R, Hall D, Purkayastha D, Pitt B (2009) Magnetic resonance imaging left ventricular mass reduction with fixed-dose angiotensin-converting enzyme inhibitor-based regimens in patients with high-risk hypertension. Hypertension 54:731–737PubMedGoogle Scholar
  57. 57.
    Boutouyrie P, Achouba A, Trunet P, Laurent S, EXPLOR Trialist Group (2010) Amlodipine-valsartan combination decreases central systolic blood pressure more effectively than the amlodipine-atenolol combination: the EXPLOR study. Hypertension 55:1314–1322PubMedGoogle Scholar
  58. 58.
    Doi M, Miyoshi T, Hirohata S, Kamikawa S, Usui S, Kaji Y, Sakane K, Ogawa H, Ninomiya Y, Kusachi S (2010) Combination therapy of calcium channel blocker and angiotensin II receptor blocker reduces augmentation index in hypertensive patients. Am J Med Sci 339:433–439PubMedGoogle Scholar
  59. 59.
    Oparil S, Melino M, Lee J, Fernandez V, Heyrman R (2010) Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: the TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study. Clin Ther 32:1252–1269PubMedGoogle Scholar
  60. 60.
    Pareek A, Chandurkar NB, Sharma R, Tiwari D, Gupta BS (2010) Efficacy and tolerability of a fixed-dose combination of metoprolol extended release/amlodipine in patients with mild-to-moderate hypertension: a randomized, parallel-group, multicentre comparison with losartan plus amlodipine. Clin Drug Investig 30:123–131PubMedGoogle Scholar
  61. 61.
    Ishimitsu T, Ohno E, Nakano N, Furukata S, Akashiba A, Minami J, Numabe A, Matsuoka H (2011) Combination of angiotensin II receptor antagonist with calcium channel blocker or diuretic as antihypertensive therapy for patients with chronic kidney disease. Clin Exp Hypertens 33:366–372PubMedGoogle Scholar
  62. 62.
    Kato J, Yokota N, Tamaki N, Kariya S, Kita T, Ayabe T, Eto T, Kitamura K (2011) Comparison of combination therapies, including the angiotensin receptor blocker olmesartan and either a calcium channel blocker or a thiazide diuretic, in elderly patients with hypertension. Hypertens Res 34:331–335PubMedGoogle Scholar
  63. 63.
    Martinez-Martin FJ, Rodriguez-Rosas H, Peiro-Martinez I, Soriano-Perera P, Pedrianes-Martin P, Comi-Diaz C (2011) Olmesartan/amlodipine vs olmesartan/hydrochlorothiazide in hypertensive patients with metabolic syndrome: the OLAS study. J Hum Hypertens 25:346–353PubMedGoogle Scholar
  64. 64.
    Matsuzaki M, Ogihara T, Umemoto S, Rakugi H, Matsuoka H, Shimada K, Abe K, Suzuki N, Eto T, Higaki J, Ito S, Kamiya A, Kikuchi K, Suzuki H, Tei C, Ohashi Y, Saruta T, Combination Therapy of Hypertension to Prevent Cardiovascular Events Trial Group (2011) Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: a randomized controlled trial. J Hypertens 29:1649–1659PubMedGoogle Scholar
  65. 65.
    Lee IT, Hung YJ, Chen JF, Wang CY, Lee WJ, Sheu WH (2012) Comparison of the efficacy and safety profiles of two fixed-dose combinations of antihypertensive agents, amlodipine/benazepril versus valsartan/hydrochlorothiazide, in patients with type 2 diabetes mellitus and hypertension: a 16-week, multicenter, randomized, double-blind, noninferiority study. Clin Ther 34:1735–1750PubMedGoogle Scholar
  66. 66.
    Ma L, Wang W, Zhao Y, Zhang Y, Deng Q, Liu M, Sun H, Wang J, Liu L (2012) Combination of amlodipine plus angiotensin receptor blocker or diuretics in high-risk hypertensive patients: a 96-week efficacy and safety study. Am J Cardiovasc Drugs 12:137–142PubMedGoogle Scholar
  67. 67.
    Ma R, Yu J, Xu D, Yang L, Lin X, Zhao F, Bai F (2012) Effect of felodipine with irbesartan or metoprolol on sexual function and oxidative stress in women with essential hypertension. J Hypertens 30:210–216PubMedGoogle Scholar
  68. 68.
    Volpe M, Christian Rump L, Ammentorp B, Laeis P (2012) Efficacy and safety of triple antihypertensive therapy with the olmesartan/amlodipine/hydrochlorothiazide combination. Clin Drug Investig 32:649–664PubMedGoogle Scholar
  69. 69.
    Yasuda G, Yatsu K, Yamamoto Y, Hirawa N (2012) Effects of carvedilol as third-line add-on therapy on blood pressure and glucose metabolism in type 2 diabetic patients with chronic renal disease stage 3 and above. Kidney Blood Press Res 36(1):131–138PubMedGoogle Scholar
  70. 70.
    Christogiannis LG, Kostapanos MS, Tellis CC, Milionis HJ, Tselepis AD, Elisaf MS (2013) Distinct effects of fixed combinations of valsartan with either amlodipine or hydrochlorothiazide on lipoprotein subfraction profile in patients with hypertension. J Hum Hypertens 27:44–50PubMedGoogle Scholar
  71. 71.
    Kojima M, Okubo S, Mizubayashi R, Isaka N, Machida H, Okamoto S, Hirota H, Takeuchi M, Kato T, Nakatani K, Mizuno O, Miyagawa K, Makino K, Okura T, Dohi Y, Ito M, Kimura G (2013) Kidney-protective effects of azelnidipine versus a diuretic in combination with olmesartan in hypertensive patients with diabetes and albuminuria: a randomized study. Nephrol Dial Transplant 28:1802–1810PubMedGoogle Scholar
  72. 72.
    M’Buyamba-Kabangu JR, Anisiuba BC, Ndiaye MB, Lemogoum D, Jacobs L, Ijoma CK, Thijs L, Boombhi HJ, Kaptue J, Kolo PM, Mipinda JB, Osakwe CE, Odili A, Ezeala-Adikaibe B, Kingue S, Omotoso BA, Ba SA, Ulasi II, Staessen JA (2013) Newer versus Older Antihypertensive Agents in African Hypertensive Patients Trial (NOAAH) Investigators. Efficacy of newer versus older antihypertensive drugs in black patients living in sub-Saharan Africa. J Hum Hypertens 27:729–735PubMedPubMedCentralGoogle Scholar
  73. 73.
    Merchant N, Rahman ST, Ahmad M, Parrott JM, Johnson J, Ferdinand KC, Khan BV (2013) Changes in biomarkers and 24 hours blood pressure in hypertensive African Americans with the metabolic syndrome: comparison of amlodipine/olmesartan versus hydrochlorothiazide/losartan. J Am Soc Hypertens 7:386–394PubMedGoogle Scholar
  74. 74.
    Nishiwaki M, Hosoai H, Ikewaki K, Ayaori M, Yamashita T, Shige H, Higashi K, Nashida Y, Shimizu S, Kijima F, Yokoyama M, Nakamura H, ABC Study Group (2013) Efficacy and effects on lipid metabolism of combination treatment with losartan + hydrochlorothiazide versus losartan + amlodipine: a 48-week prospective, multicenter, randomized, open-label trial. Clin Ther 35:461–473PubMedGoogle Scholar
  75. 75.
    Okura T, Miyoshi K, Irita J, Enomoto D, Jotoku M, Nagao T, Watanabe K, Matsuoka H, Ashihara T, Higaki J, Ehime, Study (2013) Effect of Anti-hypertensive therapy on Regression of Cardiac Hypertrophy (E-SEARCH) trial investigators. Comparison of the effect of combination therapy with an angiotensin II receptor blocker and either a low-dose diuretic or calcium channel blocker on cardiac hypertrophy in patients with hypertension. Clin Exp Hypertens 35:563–569PubMedGoogle Scholar
  76. 76.
    Sato N, Saijo Y, Sasagawa Y, Morimoto H, Takeuchi T, Sano H, Koyama S, Takehara N, Morita K, Sumitomo K, Maruyama J, Kikuchi K, Hasebe N (2013) CAMUI investigators. Combination of antihypertensive therapy in the elderly, multicenter investigation (CAMUI) trial: results after 1 year. J Hypertens 31:1245–1255PubMedGoogle Scholar
  77. 77.
    Yang L, Yu J, Ma R, Zhao F, Lin X, Liu P, Hu H, Bai F (2013) The effect of combined antihypertensive treatment (felodipine with either irbesartan or metoprolol) on erectile function: a randomized controlled trial. Cardiology 125:235–241PubMedGoogle Scholar
  78. 78.
    Ogihara T, Saruta T, Rakugi H, Saito I, Shimamoto K, Matsuoka H, Shimada K, Ito S, Horiuchi M, Imaizumi T, Takishita S, Higaki J, Katayama S, Kimura G, Umemura S, Ura N, Hayashi K, Odawara M, Tanahashi N, Ishimitsu T, Kashihara N, Morita S, Teramukai S (2014) COLM Investigators. Combinations of olmesartan and a calcium channel blocker or a diuretic in elderly hypertensive patients: a randomized, controlled trial. J Hypertens 32(10):2054–2063PubMedPubMedCentralGoogle Scholar
  79. 79.
    Oshikawa J, Toya Y, Morita S, Taguri M, Hanaoka K, Hasegawa T, Kaizu K, Kamata K, Kobayashi S, Ohtake T, Sato T, Yasuda G, Kimura K, Umemura S (2014) Angiotensin receptor blocker (ARB)-diuretic versus ARB-calcium channel blocker combination therapy for hypertension uncontrolled by ARB monotherapy. Clin Exp Hypertens 36:244–250PubMedGoogle Scholar
  80. 80.
    Suh SY, Ahn T, Bae JH, Lim DS, Lee SU, Kim YK, Hyon MS, Kim WH, Han KR, Park HK (2014) Efficacy and tolerability of amlodipine camsylate/losartan 5/100-mg versus losartan/hydrochlorothiazide 100/12.5-mg fixed-dose combination in hypertensive patients nonresponsive to losartan 100-mg monotherapy. Clin Ther 36(10):1402–1411PubMedGoogle Scholar
  81. 81.
    Uzui H, Morishita T, Nakano A, Amaya N, Fukuoka Y, Ishida K, Arakawa K, Lee JD, Tada H (2014) Effects of combination therapy with olmesartan and azelnidipine on serum osteoprotegerin in patients with hypertension. J Cardiovasc Pharmacol Ther 19:304–309PubMedGoogle Scholar
  82. 82.
    Rakugi H, Tsuchihashi T, Shimada K, Numaguchi H, Nishida C, Yamaguchi H, Shirakawa M, Azuma K, Fujita KP (2015) Add-on effect of hydrochlorothiazide 12.5 mg in Japanese subjects with essential hypertension uncontrolled with losartan 50 mg and amlodipine 5 mg. Hypertens Res 38(5):329–335PubMedGoogle Scholar
  83. 83.
    Toyoda S, Inami S, Kato T, Tsukada K, Nakamoto A, Kikegawa Y, Suzuki A, Anraku Y, Node K, Inoue T (2015) Choice of antihypertensive combination therapy based on daily salt intake. Am J Med Sci 350:160–166PubMedGoogle Scholar
  84. 84.
    K/DOQI Workgroup (2005) K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 45(4 Suppl 3):S1–S153Google Scholar
  85. 85.
    Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861–869PubMedGoogle Scholar
  86. 86.
    Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, Tuttle K, Douglas J, Hsueh W, Sowers J (2000) Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 36(3):646–661PubMedGoogle Scholar
  87. 87.
    Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, Collaborative Study Group (2001) Renoprotective effect of the angiotensin-receptor antagonist Irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345(12):851–860PubMedGoogle Scholar
  88. 88.
    Khan M, Khan RA, Islam F, Laghari J, Jamali SN (2011) To study the efficacy of Losartan on urinary uric acid excretion in Thiazide induced hyperuricemic and hypertensive patients. Pak J Pharm Sci 24(4):583–587PubMedGoogle Scholar
  89. 89.
    Rubio-Guerra AF, Arceo-Navarro A, Vargas-Ayala G, Rodriguez-Lopez L, Lozano-Nuevo JJ, Gomez-Harper CT (2004) The effect of trandolapril and its fixed-dose combination with verapamil on proteinuria in normotensive adults with type 2 diabetes. Diabetes Care 27(7):1688–1691PubMedGoogle Scholar
  90. 90.
    Susantitaphong P, Sewaralthahab K, Balk EM, Eiam-ong S, Madias NE, Jaber BL (2013) Efficacy and safety of combined vs. single renin-angiotensin-aldosterone system blockade in chronic kidney disease: a meta-analysis. Am J Hypertens 26(3):424–441PubMedPubMedCentralGoogle Scholar
  91. 91.
    Kjeldsen SE, Aksnes TA, de la Sierra A, Ruilope LM (2007) Amlodipine and valsartan: calcium channel blockers/angiotensin II receptor blockers combination for hypertension. Therapy 4(1):31–40Google Scholar
  92. 92.
    Pedrinelli R, Dell’Omo G, Melillo E, Mariani M (2000) Amlodipine, enalapril, and dependent leg edema in essential hypertension. Hypertension 35:621–625PubMedGoogle Scholar
  93. 93.
    Messerli FH, Oparil S, Feng Z (2000) Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (benazepril) with calcium antagonist (either nifedipine or amlodipine) versus high-dose calcium antagonist monotherapy for systemic hypertension. Am J Cardiol 86:1182–1187PubMedGoogle Scholar
  94. 94.
    Prasad GV (2014) Metabolic syndrome and chronic kidney disease: Current status and future directions. World J Nephrol 3(4):210–219PubMedPubMedCentralGoogle Scholar
  95. 95.
    Donnelly R (1992) Angiotensin-converting enzyme inhibitors and insulin sensitivity: metabolic effects in hypertension, diabetes, and heart failure. J Cardiovasc Pharmacol 20(Suppl 11):S38–S44PubMedGoogle Scholar
  96. 96.
    Henriksen EJ, Jacob S (2003) Modulation of metabolic control by angiotensin converting enzyme (ACE) inhibition. J Cell Physiol 196(1):171–179PubMedGoogle Scholar
  97. 97.
    Underwood PC, Adler GK (2013) The renin angiotensin aldosterone system and insulin resistance in humans. Curr Hypertens Rep 15(1):59–70PubMedPubMedCentralGoogle Scholar
  98. 98.
    Iwai M, Li HS, Chen R, Shiuchi T, Wu L, Min LJ, Li JM, Tsuda M, Suzuki J, Tomono Y, Tomochika H, Mogi M, Horiuchi M (2006) Calcium channel blocker azelnidipine reduces glucose intolerance in diabetic mice via different mechanism than angiotensin receptor blocker olmesartan. J Pharmacol Exp Ther 319(3):1081–1087PubMedGoogle Scholar
  99. 99.
    Fukao K, Shimada K, Hiki M, Kiyanagi T, Hirose K, Kume A, Ohsaka H, Matsumori R, Kurata T, Miyazaki T, Daida H (2011) Effects of calcium channel blockers on glucose tolerance, inflammatory state, and circulating progenitor cells in non-diabetic patients with essential hypertension: a comparative study between azelnidipine and amlodipine on glucose tolerance and endothelial function—a crossover trial (AGENT). Cardiovasc Diabetol 10:79.  https://doi.org/10.1186/1475-2840-10-79 CrossRefPubMedPubMedCentralGoogle Scholar
  100. 100.
    Andersson OK, Gudbrandsson T, Jamerson K (1991) Metabolic adverse effects of thiazide diuretics: the importance of normokalaemia. J Intern Med Suppl 735:89–96PubMedGoogle Scholar
  101. 101.
    Rehman A, Setter SM, Vue MH (2011) Drug-induced glucose alterations part 2: drug-induced hyperglycemia. Diabetes Spectrosc 24(4):234–238.  https://doi.org/10.2337/diaspect.24.4.234 CrossRefGoogle Scholar
  102. 102.
    Wofford MR, King DS, Harrell TK (2006) Drug-induced metabolic syndrome. J Clin Hypertens (Greenwich) 8(2):114–119Google Scholar
  103. 103.
    Arnold LW, Wang Z (2014) The HbA1c and all-cause mortality relationship in patients with type 2 diabetes is J-shaped: a meta-analysis of observational studies. Rev Diabetes Stud 11(2):138–152Google Scholar
  104. 104.
    Chen YY, Lin YJ, Chong E, Chen PC, Chao TF, Chen SA, Chien KL (2015) The impact of diabetes mellitus and corresponding HbA1c levels on the future risks of cardiovascular disease and mortality: a representative Cohort Study in Taiwan. PLoS ONE 10(4):e0123116.  https://doi.org/10.1371/journal.pone.0123116 CrossRefPubMedPubMedCentralGoogle Scholar
  105. 105.
    Li M, Hu X, Fan Y, Li K, Zhang X, Hou W, Tang Z (2016) Hyperuricemia and the risk for coronary heart disease morbidity and mortality a systematic review and dose-response meta-analysis. Sci Rep 6:19520.  https://doi.org/10.1038/srep19520 CrossRefPubMedPubMedCentralGoogle Scholar
  106. 106.
    Kuwabara M, Niwa K, Nishi Y, Mizuno A, Asano T, Masuda K, Komatsu I, Yamazoe M, Takahashi O, Hisatome I (2014) Relationship between serum uric acid levels and hypertension among Japanese individuals not treated for hyperuricemia and hypertension. Hypertens Res 37:785–789PubMedGoogle Scholar

Copyright information

© Springer Nature B.V. 2018

Authors and Affiliations

  • Punnaka Pongpanich
    • 1
  • Pasvich Pitakpaiboonkul
    • 1
  • Kullaya Takkavatakarn
    • 1
  • Kearkiat Praditpornsilpa
    • 1
  • Somchai Eiam-Ong
    • 1
  • Paweena Susantitaphong
    • 1
    Email author
  1. 1.Division of Nephrology, Department of Medicine, Faculty of Medicine, King Chulalongkorn Memorial HospitalChulalongkorn UniversityBangkokThailand

Personalised recommendations